Logo

Cambridge Isotope Laboratories, Nexomics Ink Supply Agreement

Jan 29, 2014 | staff reporter

NEW YORK (GenomeWeb News) – Cambridge Isotope Laboratories today announced an exclusive worldwide commercial supply agreement with Nexomics Biosciences.

Under the terms of the deal, Nexomics is providing protein production services, and CIL is providing global sales and marketing support. Financial and other terms were not disclosed.

Headquartered in North Brunswick, NJ, Nexomics is a structural biology and protein production CRO.

"The capabilities that Nexomics offers, such as the production and NMR analysis of isotope-enriched protein, will enhance and expand CIL's current product offering," CIL CEO Joel Bradley said in a statement.

Breaking News
The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.